Skip to main content
main-content

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Highlights

11-01-2022 | Semaglutide | News

STEP 8: Semaglutide better than liraglutide at weight-management doses

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

07-10-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

29-06-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-O: Efpeglenatide offers cardiorenal protection in type 2 diabetes

Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.

More on GLP-1 receptor agonists

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits